These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4616685)

  • 21. Computer simulations of the kinetics of irreversible enzyme inhibition by an unstable inhibitor.
    Topham CM
    Biochem J; 1986 Dec; 240(3):817-20. PubMed ID: 3827869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and kinetic evaluation of ethyl acrylate and vinyl sulfone derived inhibitors for human cysteine cathepsins.
    Breuer C; Lemke C; Schmitz J; Bartz U; Gütschow M
    Bioorg Med Chem Lett; 2018 Jun; 28(11):2008-2012. PubMed ID: 29748052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inhibition of pepsin-catalysed reactions by products and product analogues. Kinetic evidence for ordered release of products.
    Greenwell P; Knowles JR; Sharp H
    Biochem J; 1969 Jun; 113(2):363-8. PubMed ID: 4897199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of human inactive ("pro-") renin by cathepsin D and pepsin.
    Morris BJ
    J Clin Endocrinol Metab; 1978 Jan; 46(1):153-7. PubMed ID: 376540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cathepsin k inhibitor basicity on in vivo off-target activities.
    Desmarais S; Black WC; Oballa R; Lamontagne S; Riendeau D; Tawa P; Duong LT; Pickarski M; Percival MD
    Mol Pharmacol; 2008 Jan; 73(1):147-56. PubMed ID: 17940194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple method for determining kinetic constants of complexing inactivation at identical enzyme and inhibitor concentrations.
    Wang MH; Zhao KY
    FEBS Lett; 1997 Aug; 412(3):425-8. PubMed ID: 9276440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Wells-Knecht KJ; Wright LL
    Bioorg Med Chem Lett; 2005 May; 15(9):2209-13. PubMed ID: 15837295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The kinetics of hydrolysis of some synthetic substrates containing neutral hydrophilic groups by pig pepsin and chicken liver cathepsin D.
    Irvine GB; Blumsom NL; Elmore DT
    Biochem J; 1983 Apr; 211(1):237-42. PubMed ID: 6409091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pepstatin inhibits the digestion of hemoglobin and protein-polysaccharide complex by cathepsin D.
    Woessner JF
    Biochem Biophys Res Commun; 1972 May; 47(4):965-70. PubMed ID: 4260317
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of steric factors on digestibility of peptides containing aromatic amino acids by cathepsin D and pepsin.
    Keilová H; Bláha K; Keil B
    Eur J Biochem; 1968 May; 4(4):442-7. PubMed ID: 4873246
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of lactoyl-pepstatin and the pepsin inhibitor peptide on pig cathepsin D.
    Kay J; Afting EG; Aoyagi T; Dunn BM
    Biochem J; 1982 Jun; 203(3):795-7. PubMed ID: 7115318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library.
    Charlton J; Kirschenheuter GP; Smith D
    Biochemistry; 1997 Mar; 36(10):3018-26. PubMed ID: 9062133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solute accessibility to N epsilon-fluorescein isothiocyanate-lysine-23 cobra alpha-toxin bound to the acetylcholine receptor. A consideration of the effect of rotational diffusion and orientation constraints on fluorescence quenching.
    Johnson DA; Yguerabide J
    Biophys J; 1985 Dec; 48(6):949-55. PubMed ID: 3937557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precautions when determining kinetically the order of inactivation of enzymes by functionally irreversible inhibitors.
    Carlson GM
    Biochim Biophys Acta; 1984 Sep; 789(3):347-50. PubMed ID: 6236849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An aspartic acid residue at the active site of pepsin. The isolation and sequence of the heptapeptide.
    Bayliss RS; Knowles JR; Wybrandt GB
    Biochem J; 1969 Jun; 113(2):377-86. PubMed ID: 4897201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Slow-tight binding inhibition of pepsin by an aspartic protease inhibitor from Streptomyces sp. MBR04.
    Menon V; Rao M
    Int J Biol Macromol; 2012; 51(1-2):165-74. PubMed ID: 22522047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation studies of cathepsin D with diazo compounds.
    Kregar I; Stanovnik B; Tisler M; Nisi C; Gubensek F; Turk V
    Acta Biol Med Ger; 1977; 36(11-12):1927-30. PubMed ID: 616738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The inhibition of tissue acid proteinases by pepstatin.
    Barrett AJ; Dingle JT
    Biochem J; 1972 Apr; 127(2):439-41. PubMed ID: 4561921
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition of cathepsin G by 2-amino-3,1-benzoxazin-4-ones: kinetic investigations and docking studies.
    Gütschow M; Kuerschner L; Pietsch M; Ambrozak A; Neumann U; Günther R; Hofmann HJ
    Arch Biochem Biophys; 2002 Jun; 402(2):180-91. PubMed ID: 12051662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of human cathepsin D with the inhibitor pepstatin.
    Knight CG; Barrett AJ
    Biochem J; 1976 Apr; 155(1):117-25. PubMed ID: 938470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.